PreprintCited by 533Pancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsCholangiocarcinoma and Gallbladder Cancer Studies

The DOI matches its Crossref record; 394 of the 394 references it cites were found in a registry or an index.

Genetics and biology of pancreatic ductal adenocarcinoma

Open access

Ying, Haoqiang, Dey, Prasenjit, Yao, Wantong, Kimmelman, Alec C., Draetta, Giulio F., Maitra, Anirban, DePinho, Ronald A.·2016·Genes & Development

DOI 10.1101/gad.275776.115

Open this paper in CoChat — free account

Abstract

With 5-year survival rates remaining constant at 6% and rising incidences associated with an epidemic in obesity and metabolic syndrome, pancreatic ductal adenocarcinoma (PDAC) is on track to become the second most common cause of cancer-related deaths by 2030. The high mortality rate of PDAC stems primarily from the lack of early diagnosis and ineffective treatment for advanced tumors. During the past decade, the comprehensive atlas of genomic alterations, the prominence of specific pathways, the preclinical validation of such emerging targets, sophisticated preclinical model systems, and the molecular classification of PDAC into specific disease subtypes have all converged to illuminate drug discovery programs with clearer clinical path hypotheses. A deeper understanding of cancer cell biology, particularly altered cancer cell metabolism and impaired DNA repair processes, is providing novel therapeutic strategies that show strong preclinical activity. Elucidation of tumor biology principles, most notably a deeper understanding of the complexity of immune regulation in the tumor microenvironment, has provided an exciting framework to reawaken the immune system to attack PDAC cancer cells. While the long road of translation lies ahead, the path to meaningful clinical progress has never been clearer to improve PDAC patient survival.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1101/gad.275776.115

Cites

394 of 394 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
ROS function in redox signaling and oxidative stress
Schieber, M., & Chandel, N. S. (2014) · Current Biology · doi:10.1016/j.cub.2014.03.034 · Cited by 6,931
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
The chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783

Show all 392 references

Research works printed but not linked: 1

Kloppel G . 2000. WHO classification of tumours. IARC Press, Lyon, France.

Sorted by citations

Items 401–500 of 533

Illuminating the path to pancreatic cancer
Kato, H., & Bardeesy, N. M. (2024) · Cell Research · doi:10.1038/s41422-024-00982-9 · Cited by 2
The Impact of Peroxiredoxin 3 on Molecular Testing, Diagnosis, and Prognosis in Human Pancreatic Ductal Adenocarcinoma
Kakehashi, A., Suzuki, S., Nishidoi, Y., Hagihara, A., Ikenaga, H., Shiota, M., Qiu, G., Noura, I., Kuwae, Y., Vachiraarunwong, A., et al. (2025) · Cancers · doi:10.3390/cancers17132212 · Cited by 2
Epigenetics: Dissecting Gene Expression Alteration in PDAC
Abukiwan, A., & Berger, M. R. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.80585 · Cited by 2
Desmoplastic Reaction In Pancreatic Ductal Adenocarcinoma
Aghamaliyev, U., Hajiyeva, Y., & Rückert, F. (2016) · Pancreas - Open Journal · doi:10.17140/poj-1-107 · Cited by 2
UXT antisense RNA 1 sever as a novel prognostic long non-coding RNA in early stage pancreatic ductal adenocarcinoma patients after receiving pancreaticoduodenectomy
Liao, X., Huang, R., Wang, X., Huang, K., Yang, C., Zhou, X., Han, C., Su, H., Ye, X., Liu, K., et al. (2021) · Journal of Cancer · doi:10.7150/jca.46084 · Cited by 2
Phytochemical based sestrin2 pharmacological modulators in the treatment of adenocarcinomas
Alausa, A. O., Victor, U. C., Celestine, U. O., Eweje, I. A., Balogun, T. A., Adeyemi, R. O., Olatinwo, M., Ogunlana, A. T., Oladipo, O. O., & Olaleke, B. (2021) · Phytomedicine Plus · doi:10.1016/j.phyplu.2021.100133 · Cited by 2
Animal Modeling of Pancreatitis-to-Cancer Progression
Martinelli, P., & Real, F. X. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_66 · Cited by 2
Sustained Weight Loss, Weight Cycling, and Weight Gain During Adulthood and Pancreatic Cancer Incidence in the Women’s Health Initiative
Schwalb, M. E., Smith‐Warner, S. A., Hou, J. Y., Rohan, T. E., Snetselaar, L. G., Luo, J., & Genkinger, J. M. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac016 · Cited by 2
Trends and Hot Spots of Macrophages Linked to Metabolic Syndrome: A Comprehensive Bibliometric and Visualization Analysis (2014–2024)
Zhang, Y., He, Q., Cong, X., Qiu, H., & Hua, C. (2025) · Mediators of Inflammation · doi:10.1155/mi/9487093 · Cited by 1
Colesterolo LDL, linfociti e proteine totali nel liquido cistico: promettenti biomarcatori per le neoplasie mucinose papillari intraduttali
Contran, N., Nordi, E., Davanzo, V., Moz, S., Galozzi, P., Aita, A., Fantin, A., Cristofori, C., Fogar, P., Montagnana, M., et al. (2025) · Biochimica Clinica · doi:10.23736/s0393-0564.25.00046-9 · Cited by 1
The effect of CD40 agonist antibody therapy on the pancreatic cancer microenvironment
Ma, Y., Ding, J. W., & Chen, Y. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04532-x · Cited by 1
Dual inhibition of FACT and RRM2 suppresses the progression of pancreatic ductal adenocarcinoma driven by the oncohistone H2BG53D
Qin, T., Wan, Y. C. E., Hu, S., Chen, J., Zhu, X., Zhou, J., Chen, Y., Wang, X., Zheng, Z., Chan, L. L., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116596 · Cited by 1
Multimodal profiling of pancreatic cancer reveals a TIMP-1-dominated secretory profile determining pro-tumor immunoinstruction in human cancers
Frädrich, J., Reyes, C. M., Hendel, M., Brunner, V., Toledo, B., Manevski, D., Sommer, A., Häußler, D., Beck, D., Lucarelli, D., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102546 · Cited by 1
Radiological Findings Post Autologous Fat Grafting and Breasts Procedures: Avoiding False Positive Results
Fleury, E. D. F. C. (2026) · ANZ Journal of Surgery · doi:10.1111/ans.70583 · Cited by 1
Cell Cycle Machinery and Its Alterations in Pancreatic Cancer
Kojima, Y., Maskey, R. S., & Machida, Y. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_74 · Cited by 1
Recent Advancements for the Management of Pancreatic Cancer: Current Insights
Ali, N., & Srivastava, N. (2021) · Current Cancer Therapy Reviews · doi:10.2174/1573394717666210625153256 · Cited by 1
A novel nanoprobe-based assay for detecting K-ras mutations in plasma and stool samples from patients with pancreatic cancer: value in diagnosis and prognosis evaluation
Chen, F., Wang, X., Qi, L.-F., Mo, J., & Zhong, Z. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.07.07 · Cited by 1
Perioperative Management of Patients with Pancreatic Cancer - the ERAS Protocols
Ciocan, R. A., Ciocan, A., Zaharie, F. V., Popa, C., Schlanger, D., Alexa, A. L., Ionescu, D. C., & Hajjar, N. A. (2022) · Chirurgia · doi:10.21614/chirurgia.2761 · Cited by 1
Growth factors reviews
Li, X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15793-6.00001-9 · Cited by 1
DNA METHYLATION SEQUENCING: A PROMISING TOOL FOR PANCREATIC CANCER DIAGNOSIS
Nitin, M. (2024) · Indian Journal of Health Care Medical & Pharmacy Practice · doi:10.59551/ijhmp/25832069/2024.5.1.140 · Cited by 1
Pancreatic adenocarcinoma in a patient with a germline RB1 pathogenic variant
Patel, R. J., Fountzilas, C. K., Horowitz, M., Schultz, E., Clayback, K. M., Knudsen, E. S., Witkiewicz, A. K., & Onel, K. (2025) · Familial Cancer · doi:10.1007/s10689-025-00475-7 · Cited by 1
A Topical Report on the Design Principles of Metabolism
Halbrook, C. J., Lee, H., Cantley, L. C., & Lyssiotis, C. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-61401-4_2 · Cited by 1
Animal Modeling of Pancreatitis-to-Cancer Progression
Martinelli, P., & Real, F. X. (2017) · Springer eBooks · doi:10.1007/978-1-4939-6631-8_66-1 · Cited by 1
Zooming in on the cell biology of disease
Perera, R. M. (2021) · Molecular Biology of the Cell · doi:10.1091/mbc.e21-09-0459 · Cited by 1
EGLN Inhibition Reduces Gastrointestinal Radiation Toxicity and Improves Survival in a Murine Model of Locally Advanced Pancreatic CancerPreprint
Fujimoto, T. N., Colbert, L. E., Molkentine, J. M., Baseler, L. J., Deorukukhar, A., Kingsley, C. V., Tailor, R. C., Sawakuchi, G. O., & Taniguchi, C. M. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/195610 · Cited by 1
Desenvolvimento de xenotransplantes de tumores pancreáticos humanos para varredura genética de alvos moleculares com potencial terapêutico
de Moraes, L. B. D. C. E. A. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.46.2019.tde-07052019-110949 · Cited by 1
Differential expression of methyltransferases METTL1, METTL6 and METTL10 is associated with decreased overall survival in pancreatic ductal adenocarcinoma.Preprint
Mamoor, S. (2019) · doi:10.31219/osf.io/wy5te · Cited by 1
Ppard Is Essential in Acceleration of Pancreatic Ductal Adenocarcinoma Development by High-Fat Diet in Mutant Kras MicePreprint
Liu, Y., Deguchi, Y., Wei, D., Moussalli, M. J., Li, D., Wang, H., Valentin, L. A., Colby, J. K., Liu, F., Wang, J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.04.412320 · Cited by 1
A cancer cell-intrinsic GOT2-PPARδ axis suppresses antitumor immunityPreprint
Sanford-Crane, H. S., Abrego, J., Oon, C. H., Xu, X., Nagarajan, S., Bhattacharyya, S., Tontonoz, P., & Sherman, M. H. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.25.424393 · Cited by 1
YY1 Promotes Pancreatic Cancer Cell proliferation by Enhancing Mitochondrial RespirationPreprint
Jiang, M., Li, B., Wang, J., Liao, J. P., Wu, M., Yuan, X., Fang, H., & Shen, L. (2022) · Research Square · doi:10.21203/rs.3.rs-1466742/v1 · Cited by 1
Molecular Pathology of Pancreatic Ductal Adenocarcinoma
Insilla, A. C., Giordano, M., & Campani, D. (2022) · Encyclopedia of pathology · doi:10.1007/978-3-030-62416-3_5572 · Cited by 1
Palmitoyl transferase ZDHHC20 promotes pancreatic cancer metastasisPreprint
Tomić, G., Sheridan, C., Refermat, A. Y., Baggelaar, M. P., Sipthorp, J., Sudarshan, B., Ocasio, C. A., Suárez‐Bonnet, A., Priestnall, S. L., Herbert, E., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2648300/v1 · Cited by 1
Modulation of Gene Expression During Stages of Liver Colonization by Pancreatic Cancer in a Rat Model
Al-Taee, K. K., Adwan, H., & Berger, M. R. (2016) · InTech eBooks · doi:10.5772/64335
Estudos proteômicos da transição epitélio-mensenquimal induzida por TGF-β e EGF em linhagens celulares de câncer de pâncreas
Canchaya, G. S. (2017) · doi:10.11606/t.17.2017.tde-05012017-095632
Metabolism in Pancreatic Cancer
Poursaitidis, I., & Lamb, R. F. (2017) · Springer eBooks · doi:10.1007/978-1-4939-6631-8_68-1
PET Imaging in Pancreatic Cancer
Li, Y., & Wang, X. (2019) · SDRP Journal of Food Science & Technology · doi:10.25177/jfst.4.3.ra.493
Stromal and epithelial mechanisms of chemotherapeutic resistance in pancreatic cancer
Patzak, M. S. (2019) · doi:10.53846/goediss-7441
Nuclear NFATc1/Smad3 complexes in Smad4-deficient pancreatic cancer
Hasselluhn, M. C. (2019) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7778
Role of Autophagy in Cancer Cell Metabolism
Pedroza, D. A., Chandel, V., Kumar, D., Doddapattar, P., Biradar, M. S., Lakshmanaswamy, R., Gadad, S. S., & Choudhari, R. (2020) · Springer eBooks · doi:10.1007/978-981-15-1991-8_6
Development of Novel Therapeutic Strategies for Pancreatic Cancer Treatment
Setua, S. (2020) · doi:10.21007/etd.cghs.2020.0503
Análise integrada de alterações somáticas e transcricionais em tumores de pâncreas
Pellegrina, D. V. D. S. (2020) · doi:10.11606/t.95.2020.tde-25062020-165840
UDP-glucose pyrophosphorylase 2, a regulator of glycosylation and glycogen, is essential for pancreatic cancer growthPreprint
Wolfe, A. L., Zhou, Q., Toska, E., Galeas, J., Ku, A. A., Koche, R. P., Bandyopadhyay, S., Scaltriti, M., Lebrilla, C. B., McCormick, F. P., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.13.337998
Gene modules and non-coding RNAs involved in pancreatic tumorigenesis through acinar ductal metaplasiaPreprint
Zhang, H., Shi, B., Gao, Z., & Gao, B. (2020) · doi:10.21203/rs.3.rs-31936/v1
Islet Inflammation: The Link between Type 2 Diabetes and Pancreatic Cancer
Mukhuty, A. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98538
Activated Pancreatic Stellate Cells Promote Acinar Duct Metaplasia by Disrupting Mitochondrial Respiration and Releasing Reactive Oxygen Species
Xiang, H., Guo, F., Zhou, Q., Tao, X., & Dong, D. (2021) · Current Chinese Science · doi:10.2174/2210298101666210928122952
Overexpressing PLOD Family Genes Predict Poor Prognosis In Pancreatic CancerPreprint
Zhang, J., Tian, Y. Z., Mo, S., & Fu, X. (2021) · Research Square · doi:10.21203/rs.3.rs-895700/v1
Stellungnahme zur Nutzenbewertung Olaparib (neues Anwendungsgebiet, Pankreaskarzinom, Erhaltungstherapie)
(2021) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1484-8161
Therapeutic strategies targeting Kv10.1 in PDAC
Zahed, F. (2017) · doi:10.53846/goediss-6092
The DNA damage kinases MK2, Chk1 and the chromatin remodeling factor CHD8 determine the cellular outcome after replicative stress and DNA damage
Binkowski, A. M. (2021) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8524
Recent advances in understanding pancreatic cancer
Stott, M. C., Oldfield, L. S., Hale, J. J., Costello, E., & Halloran, C. M. (2022) · Faculty Reviews · doi:10.12703/r/11-10
Gene modules and non-coding RNAs involved in pancreatic tumorigenesis through acinar ductal metaplasiaPreprint
Zhang, H., Shi, B., Gao, Z., & GAO, B. (2020) · doi:10.21203/rs.3.rs-31936/v2
Peer Review #2 of "GBP2 as a potential prognostic biomarker in pancreatic adenocarcinoma (v0.1)"
(2021) · PeerJ · doi:10.7287/peerj.11423v0.1/reviews/2
The ECM and CAFs interact to differentially regulate PDAC parenchymal (CPC) and CSC phenotypes to determine pancreatic ductal adenocarcinoma (PDAC) progressionPreprint
Cannone, S., Greco, M. R., Guizouarn, H., Soriani, O., Tomasini, R., Casavola, V., Zeeberg, K., Reshkin, S. J., & Cardone, R. A. (2019) · Research Square · doi:10.21203/rs.2.13193/v1
Integrin alpha 2 (Itga2), CD49b, is differentially expressed in pancreatic ductal adenocarcinoma.Preprint
Mamoor, S. (2020) · doi:10.31219/osf.io/4jwq8
Faculty Opinions recommendation of Cell of origin influences pancreatic cancer subtype.
Sosa‐Pineda, B. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.739647870.793585324
Cell Cycle Machinery and Its Alterations in Pancreatic Cancer
Kojima, Y., Maskey, R. S., & Machida, Y. (2017) · Springer eBooks · doi:10.1007/978-1-4939-6631-8_74-1
Molecular Pathology of Pancreatic Ductal Adenocarcinoma
Insilla, A. C., Giordano, M., & Campani, D. (2020) · Encyclopedia of pathology · doi:10.1007/978-3-319-28845-1_5572-1
Peer Review #1 of "GBP2 as a potential prognostic biomarker in pancreatic adenocarcinoma (v0.1)"
(2021) · PeerJ · doi:10.7287/peerj.11423v0.1/reviews/1
Opportunities and Resistance to Signal-targeted Therapies in Pancreatic Cancer: What Can We Learn from Proteomic Studies?Preprint
Cintas, C., Douché, T., & Guillermet‐Guibert, J. (2018) · Preprints.org · doi:10.20944/preprints201802.0011.v1
KLF5-mediated Eppk1 expression promotes cell proliferation in cervical cancer via the p38 signaling pathwayPreprint
Pan, Z., Liu, X., Chang, Q., Zhang, J., Hua, N., Li, G., & Ma, D. (2020) · doi:10.21203/rs.3.rs-28654/v1
Peer Review #2 of "GBP2 as a potential prognostic biomarker in pancreatic adenocarcinoma (v0.2)"
(2021) · PeerJ · doi:10.7287/peerj.11423v0.2/reviews/2
TP53-status dependent oncogenic EZH2 Activity in Pancreatic Cancer
Versemann, L. (2022) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9359
Identification of early diagnosis markers of pancreatic ductal adenocarcinoma (PDAC) using publicly available transcriptomic tumour and blood sample dataPreprint
Sionakidis, A., Lalagkas, P. N., Malousi, A., & Vizirianakis, I. S. (2022) · Research Square · doi:10.21203/rs.3.rs-2172022/v1
Identification of early diagnosis markers of pancreatic ductal adenocarcinoma (PDAC) using publicly available transcriptomic tumor and blood sample dataPreprint
Sionakidis, A., Lalagkas, P. N., Malousi, A., & Vizirianakis, I. S. (2022) · Research Square · doi:10.21203/rs.3.rs-2172022/v2
Targeting T cell checkpoints and myeloid suppressor cells is effective in pancreatic cancer
(2023) · Nature Cancer · doi:10.1038/s43018-022-00501-y
Differential expression of SLC39A5 in pancreatic cancer.Preprint
Mamoor, S. (2023) · doi:10.31219/osf.io/vfq73
Differential expression of PDIA2 in pancreatic cancer.Preprint
Mamoor, S. (2023) · doi:10.31219/osf.io/htzr6
Differential expression of GSTA2 in pancreatic cancer.Preprint
Mamoor, S. (2023) · doi:10.31219/osf.io/yvma4
Differential expression of SLC43A1 in pancreatic cancer.Preprint
Mamoor, S. (2023) · doi:10.31219/osf.io/skdwg
Differential expression of SEL1L in pancreatic cancer.Preprint
Mamoor, S. (2023) · doi:10.31219/osf.io/mjksy
Differential expression of CBS in pancreatic cancer.Preprint
Mamoor, S. (2023) · doi:10.31219/osf.io/bxq24
Differential expression of SLC41A1 in pancreatic cancer.Preprint
Mamoor, S. (2023) · doi:10.31219/osf.io/km4xj
Differential expression of GMNN in pancreatic cancer.Preprint
Mamoor, S. (2023) · doi:10.31219/osf.io/4wdtu
Differential expression of AQP8 in pancreatic cancer.Preprint
Mamoor, S. (2023) · doi:10.31219/osf.io/4bamv
Differential expression of PSAT1 in pancreatic cancer.Preprint
Mamoor, S. (2023) · doi:10.31219/osf.io/thkbw
Discovering potential stabilizers for KRAS22RT G-quadruplex DNA: an alternative next generation approach to treat pancreatic cancer
Yousaf, M., Fatima, D., Amin, J., Noureen, A., & Fatmi, M. Q. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2174188
Data from KDM6A Loss Recruits Tumor-Associated Neutrophils and Promotes Neutrophil Extracellular Trap Formation in Pancreatic Cancer
Yang, J., Jin, L., Kim, H. S., Tian, F., Yi, Z., Bedi, K., Ljungman, M. E., di Magliano, M. P., Crawford, H. C., & Shi, J. (2023) · doi:10.1158/0008-5472.c.6514316.v1
Data from Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
Singh, K., Lin, J., Lecomte, N., Mohan, P., Askan, G., Sanghvi, V. R., Jiang, M., Grbovic-Huezo, O., Burčul, A., Stark, S. G., et al. (2023) · doi:10.1158/0008-5472.c.6513651.v1
Data from Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice
Park, W., O'Connor, C. A., Bandlamudi, C., Forman, D., Chou, J. F., Umeda, S., Reyngold, M., Varghese, A. M., Keane, F., Balogun, F. O., et al. (2023) · doi:10.1158/1078-0432.c.6532713.v1
Data from Cell of Origin Influences Pancreatic Cancer Subtype
Flowers, B. M., Xu, H., Mulligan, A. S., Hanson, K. J., Seoane, J. A., Vogel, H. S., Curtis, C. N., Wood, L. D., & Attardi, L. D. (2023) · doi:10.1158/2159-8290.c.6547895.v1
Apolipoprotein B/Apolipoprotein A ratio: a novel prognostic factor for pancreatic cancerPreprint
Li, C., Yang, X., Zhong, Y., Wang, W., Jin, X., Bian, L., & wang, X. (2023) · Research Square · doi:10.21203/rs.3.rs-2823601/v1
TRP Channels Interactome in Pancreatic Ductal Adenocarcinoma: A Potential Therapeutic Target
Khalaf, A. T., Wei, Y., Kadir, S. Y. A., Zainol, J., & Oglah, Z. (2023) · International Electronic Conference on Biomedicines (IECBM) · doi:10.3390/ecb2023-14133
Calligraphy tool offers clues to the origin of pancreatic cancer
Bednar, F., & di Magliano, M. P. (2023) · Nature · doi:10.1038/d41586-023-02518-4
Metabolomics of Gastrointestinal Cancers
Nannini, G., Meoni, G., Tenori, L., & Amedei, A. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2023_182
Identification of diagnostic markers of pancreatic ductal adenocarcinoma using transcriptomic tumour and blood sample data
Sionakidis, A., Lalagkas, P. N., Malousi, A., & Vizirianakis, I. S. (2023) · Clinical and Translational Discovery · doi:10.1002/ctd2.248
Genetic Insight into the Regulation of Iron Metabolism by Exocrine Enzymes as a New Strategy to Treat Pancreatic CancerPreprint
Chu, T., Zhao, Y., Chen, L., Liu, H., Zhang, J., Peng, X., Lou, F., Liu, H., Duan, K., Liu, H., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4604835
BAZ2A-SUV39H1-SMAD2/3-OCT4 regulates stemness, cell cycle exit and chemoresistance in pancreatic ductal adenocarcinomaPreprint
Militi, S., Liu, F., Nibhani, R., Mouti, M. A., Pook, M., Cai, L., Choo, S. W., & Pauklin, S. (2023) · Research Square · doi:10.21203/rs.3.rs-3570401/v1
Long noncoding RNA BANCR promotes lymphangiogenesis and lymph node metastasis of pancreatic carcinoma by regulating VEGF-C/VEGFR-3 signaling pathwayPreprint
Hao, S., Li, Z., Ji, Y., Sun, H., Nie, F., Hu, Y., Zhang, B., Ji, K., Ding, Y., & Han, W. (2023) · Research Square · doi:10.21203/rs.3.rs-3774468/v1
Unraveling the Significance of Mg2+ Dependency and Nucleotide Binding Specificity of H-RAS
Tagad, A., & Patwari, G. N. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.3c06998
Additional file 1 of Genomic analysis reveals HDAC1 regulates clinically relevant transcriptional programs in Pancreatic cancer
Wright, C., Gordon, E. R., & Cooper, S. J. (2023) · Figshare · doi:10.6084/m9.figshare.24630276
Supplementary Data S1 from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study
Markussen, A., Johansen, J. S., Larsen, F. O., Theile, S., Hasselby, J. P., Willemoe, G. L., Lorentzen, T., Madsen, K. S., Høgdall, E. V. S., Poulsen, T. S., et al. (2024) · doi:10.1158/1078-0432.26710999.v1
Supplementary Data S1 from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study
Markussen, A., Johansen, J. S., Larsen, F. O., Theile, S., Hasselby, J. P., Willemoe, G. L., Lorentzen, T., Madsen, K. S., Høgdall, E. V. S., Poulsen, T. S., et al. (2024) · doi:10.1158/1078-0432.26710999
Beyond Insulin: A Deeper Dive into Pancreatic Disease
Sharma, S., Sharma, P., & Rani, N. (2024) · Current Nutrition & Food Science · doi:10.2174/0115734013307659240820060042
On the Effects of Gene Mutations in Pancreatic Tumorigenesis, Depending on the Cell Types and Times When They Are Induced
Jacquemin, P. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.101394
Genetics and biology of pancreatic ductal adenocarcinoma
Jai, M., & Mozdziak, P. E. (2024) · Medical Journal of Cell Biology · doi:10.2478/acb-2024-0006 · Cited by 1
RASopathy Genes: Germline Risk and Somatic Cancers
Ney, G. M., Kratz, C. P., & Stewart, D. R. (2024) · Springer eBooks · doi:10.1007/978-3-031-62945-7_22
Tumor Immune Microenvironment Differences Associated With Racial Disparities in Pancreatic Cancer
Gao, Z., Azar, J. H., Erstad, D. J., Sun, Z., Janakiraman, H., Chung, D., Lewin, D., Lee, H., Buren, G. V., Fisher, W. P., et al. (2025) · Journal of Surgical Research · doi:10.1016/j.jss.2025.01.005
Comprehensive molecular analysis of 26 newly established human pancreatic ductal adenocarcinoma cell lines reveals two clusters with variating drug sensitivities
Maeng, J. E., Kim, J.-H., Kim, S., Yun, W., Kwon, W., Han, Y., Oh, D. Y., Lee, S. H., Jang, J., & Ku, J. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03671-8 · Cited by 1
Investigating the prognostic value of KCNN4 gene expression in human pancreatic adenocarcinoma by bioinformatic analysisPreprint
Islam, S. S., Tushar, M. M. H., Sarkar, B., Moni, R., Zohora, U. S., & Rahman, M. S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.26.650766
Collagen XVII Promotes Pancreatic Ductal Adenocarcinoma Tumor Growth through Regulation of PIK3R5
Hank, T. P., Li, A., Bolm, L., Sandini, M., Baba, T., Petruch, N., Strässer, J., Taniue, K., Harrison, J. M., Mino-Kenudson, M. A., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0392

Authors: Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
Dana-Farber Cancer Institute (US)
ORCID: Ying, Haoqiang
Dey, Prasenjit
Yao, Wantong
Kimmelman, Alec C.
Draetta, Giulio F.
Maitra, Anirban
DePinho, Ronald A.
Venue: Genes & Development
Publisher: Cold Spring Harbor Laboratory
Published: 2016-02-15
Volume: 30
Issue: 4
Pages: 355-385
ISSN: 0890-9369 (ISSN-L)
1549-5477
DOI: 10.1101/gad.275776.115
OpenAlex: W4295846302
Cited by: 527
References: 392
Citations by year: 2026: 20 · 2025: 33 · 2024: 44 · 2023: 68 · 2022: 56 · 2021: 75 · 2020: 57 · 2019: 48 · 2018: 51 · 2017: 59 · 2016: 16
Type: posted content
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc
Locations: Genes & Development (publishedVersion, cc-by-nc)
HighWire Press Open Archive (submittedVersion)
Funders: Sheikh Ahmed Center for Pancreatic Cancer Research
Pancreatic Cancer Moon Shot at the University of Texas MD Anderson Cancer Center
University of Texas Star Award (W81XWH-14-1-0429)
Department of Defense (U01DK108328, U01CA196403)
Odyssey Fellowship (Anne Eastland Spears Fellowship in GI Cancer Research)
University of Texas MD Anderson Cancer Center (RSG-13-298-01-TBG)
American Cancer Society (R01GM095567, R01CA157490, R01CA188048)
National Institutes of Health (14-90-25-DRAE, P01CA117969)
American Association for Cancer Research (W81XWH-11-1-0418)
Topics: Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
Keywords: pancreatic ductal adenocarcinoma, cancer genomics, molecular classification, cancer metabolism, DNA repair, tumor microenvironment, cancer immunotherapy, drug discovery, obesity, metabolic syndrome, preclinical models

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Genetics and biology of pancreatic ductal adenocarcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks